Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 9, 1999, Pages 3140-3145

  Landstedt Hallin, L ^a   Adamson, U ^a   Lins, P E ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; GLIBENCLAMIDE; GLUCAGON; GLUCOSE; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HORMONAL REGULATION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL;

EID: 0033304547     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.9.3140     Document Type: Article

References (55)

1. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
3. Long-term glycemic control relates to mortality in type II diabetes
4. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
5. The effects of improved glycemic control on complications in type 2 diabetes
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
7. Glucose counterregulation: Prevention and correction of hypoglycemia in humars
8. Evidence against important catecholarrine compensation for absent glucagon counterregulation
9. Treatment of NIDDM: Progressive requirement for polypharmacy to attain glycaemic goals
10. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis
11. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM
12. The Berson memorial lecture. Insulin-glucagon relationships in the defense against hypoglycemia
13. Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycaemia and hypoglycaemia
14. Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: Comparison with a radioenzymatic method
15. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms
16. Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas
17. Interplay of nutrients and hormones in the regulation of glucagon release
18. Autonomic mediation of glucagon secretion during hypoglycemia: Implications for impaired α-cell responses in type 1 diabetes
19. Intraislet insulin-glucagon-somatostatin relationships
20. New perspectives on the microvasculature of the islets of Langerhans in the rat
21. Insulin within islets is a physiologic glucagon release inhibitor
22. In vivo inhibition of glucagon secretion by paracrine beta cell activity in man
23. Suppression of counterregulatory hormone response to hypoglycemia by insulin per se
24. A high concentration of circulating insulin suppresses the glucagon response to hypoglycemia in normal man
25. Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man. Role of the β cell and arterial hyperinsulinemia
26. Effect of physiological hyperin-sulinemia on counterregulatory hormone responses during hypoglycemia in humans
27. Effect of glucose/sulfonylurea interaction on release of insulin, glucagon, and somatostatin from isolated perfused rat pancreas
28. Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas
29. Pancreatic glucagon release and sulphonylureas
30. Effects of hypoglycemic sulfonamides on glucagon and insulin secretion in ducks and dogs
31. Failure of sulfonylureas to suppress plasma glucagon in man
32. Unaltered glucagon secretion after seven days of sulphonylurea administration in normal subjects
33. Glucagon response to arginine after treatment of diabetes mellitus
34. The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal
35. Suppression of glucagon secretion during a tolbutamide infusion in normal, and noninsulin-dependent diabetic subjects
36. A new method for comparing portal and peripheral venous insulin delivery in humans: Tolbutamide vs. insulin infusion
37. The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans
38. Glibenclamide decreases glucagon release during mild hypoglycaemia
39. Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects
40. Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients
41. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions
42. Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes
43. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
44. Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus
45. Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis
46. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM
47. Lack of glucagon response to hypoglycemia in diabetes: Evidence for an intrinsic pancreatic alpha cell defect
48. Hormonal, metabolic and cardiovascular responses to hypoglycaemia in type 1 (insulin-dependent) diabetes with and without residual B cell function
49. C-Peptide in NIDDM
50. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes
51. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents
52. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas
53. Glibenclamide-associated hypoglycaemia: A report on 57 cases
54. Hypoglycemia: A major problem in the management of diabetes in the elderly
55. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin, resistance